Ken Griffin Keros Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 11,300 shares of KROS stock, worth $749,303. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,300
Previous 1,200
841.67%
Holding current value
$749,303
Previous $54,000
1114.81%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.3MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$167 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$126 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$123 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$101 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$100 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.71B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...